Dicerna Pharmaceuticals Inc
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2026-06-01Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors
- Phase 3Active Not Recruitingreadout ~2030-04-01Long Term Extension Study in Patients With Primary Hyperoxaluria
- Phase 2Recruitingreadout ~2031-12-30Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent0 acquisitions12 disposalsnet −316,306 shares · last 12
| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Koppel AdamDirector | Dec 28, 2021 | U | 3,333 | $38.25 |
| Zeng LingOfficer — Chief Legal Officer & Sec'y | Dec 28, 2021 | U | 5,032 | $38.25 |
| Weissman James BOfficer — Chief Operating Officer & EVP | Dec 28, 2021 | U | 18,100 | $38.25 |
| Smith CynthiaDirector | Dec 28, 2021 | U | 3,333 | $38.25 |
| Pagan Douglas W.Officer — Chief Financial Officer | Dec 28, 2021 | U | 7,775 | $38.25 |
| Kozin Marc DDirector | Dec 28, 2021 | D | 6,333 | $38.25 |
| Hoffman Stephen JDirector | Dec 28, 2021 | U | 16,157 | $38.25 |
| Gray Patrick M.Director | Dec 28, 2021 | U | 3,333 | $38.25 |
| Freed Martin IDirector | Dec 28, 2021 | U | 3,333 | $38.25 |
| Fambrough DouglasOfficer — Chief Executive Officer | Dec 28, 2021 | D | 231,431 | $38.25 |
| Doberstein Stephen KDirector | Dec 28, 2021 | U | 3,333 | $38.25 |
| Ciappenelli Robert D.Officer — Chief Strategy Officer | Dec 28, 2021 | U | 14,813 | $38.25 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventDec 28, 2021
- Entered a material agreement · Other material eventNov 18, 2021
- Results of operationsNov 9, 2021
- Results of operationsAug 9, 2021
- Regulation FD disclosureAug 6, 2021
- Shareholder voteJun 4, 2021
- Results of operationsMay 6, 2021
- Entered a material agreementApr 12, 2021
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2022
- 15-12BFORM 15-12BJan 10, 2022
- EFFECTDec 30, 2021
- EFFECTDec 30, 2021
- EFFECTDec 30, 2021
- EFFECTDec 30, 2021
- 4FORM 4 SUBMISSIONDec 29, 2021
- 4FORM 4Dec 29, 2021
- 4FORM 4Dec 29, 2021
- 4FORM 4Dec 29, 2021
- 4FORM 4Dec 29, 2021
- 4FORM 4Dec 29, 2021
- 4FORM 4Dec 29, 2021
- 4FORM 4Dec 29, 2021
- 4FORM 4Dec 29, 2021